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In Brief
Pharmacological activation of brown adi-
pose tissue (BAT) thermogenesis and en-
ergy dissipation, a process mediated by
UCP1, may be useful to counter the en-
ergy imbalance that engenders obesity.
Galmozzi et al. have developed an in vivo
model to monitor UCP1 expression in real
time and identified a small molecule that
increases UCP1 levels. Mice treated with
this molecule show greater energy
expenditure upon adrenergic stimulation.
Discovery of compounds with this ability
is an important stride toward enhancing
BAT function in obese individuals.
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Obesity develops when energy intake chronically
exceeds energy expenditure. Because brown adi-
pose tissue (BAT) dissipates energy in the form of
heat, increasing energy expenditure by augmenting
BAT-mediated thermogenesis may represent an
approach to counter obesity and its complications.
The ability of BAT to dissipate energy is dependent
on expression of mitochondrial uncoupling protein
1 (UCP1). To facilitate the identification of phar-
macological modulators of BAT UCP1 levels, which
may have potential as antiobesity medications, we
developed a transgenic model in which luciferase
activity faithfully mimics endogenous UCP1 expres-
sion and its response to physiologic stimuli. Pheno-
typic screening of a library using cells derived from
this model yielded a small molecule that increases
UCP1 expression in brown fat cells and mice. Upon
adrenergic stimulation, compound-treated mice
showed increased energy expenditure. These tools
offer an opportunity to identify pharmacologic mod-
ulators of UCP1 expression and uncover regulatory
pathways that impact BAT-mediated thermogenesis.
INTRODUCTION
The epidemic of obesity poses a dire public health problem, for
obesity is a major risk factor for development of insulin resis-
tance, type 2 diabetes, cardiovascular disease, and cancer.
Obesity is the result of a sustained energy imbalance in which
intake exceeds expenditure. Current antiobesity drugs work by
limiting energy intake, either through suppression of appetite
or inhibition of intestinal lipid absorption (Kim et al., 2014). These
medications are effective, but side effects often associated with
long-term use, such as depression or steatorrhea, limit patient1584 Cell Reports 9, 1584–1593, December 11, 2014 ª2014 The Autcompliance. The discovery of brown adipose tissue (BAT) in
adult humans and its correlation with body mass index (Cypess
et al., 2009; Saito et al., 2009; van Marken Lichtenbelt et al.,
2009; Virtanen et al., 2009) suggests that active BATmay protect
from obesity. BAT dissipates energy in the form of heat, thus
increasing energy expenditure. It is thought that pharmacolog-
ical activation of BAT thermogenesis may be an alternative
approach to alter energy balance, one complementary to exist-
ing obesity medications (Nedergaard and Cannon, 2010; Kaji-
mura and Saito, 2014).
The ability of BAT to produce heat is dependent on expression
of the BAT-specific uncoupling protein 1 (UCP1). In response to
exposure to cold or a high-fat diet, UCP1 reduces the mitochon-
drial membrane potential and uncouples cellular respiration from
ATP synthesis, thereby generating heat. Because other UCP
proteins (e.g., UCP2 and UCP3) do not contribute to adaptive
thermogenesis (Golozoubova et al., 2001), UCP1 is thought to
be solely responsible for adaptive nonshivering thermogenesis.
UCP1-null mice are intolerant to cold (Enerba¨ck et al., 1997)
and develop obesity at thermoneutral conditions (Feldmann
et al., 2009). In contrast, transgenic expression of UCP1 in fat in-
creases oxygen consumption in BAT and epididymal white adi-
pose tissue (WAT) and reduces body weight gain (Kopecky
et al., 1995). Contrary to the mechanism of action of small-mole-
cule mitochondrial uncouplers such as 2,4-dinitrophenol that
proved too toxic as weight loss agents (Grundlingh et al.,
2011), UCP1-mediated uncoupling is a highly regulated process
that requires direct binding of long-chain free fatty acids to UCP1
in response to physiologic cyclic AMP (cAMP) signaling (Fedor-
enko et al., 2012). A pharmacological approach to increase
UCP1 expression and activity in adipose tissue is thus likely to
constitute a safer avenue to enhance whole-body thermogenic
capacity and energy expenditure. To test this concept, it is of
great interest to identify small molecules that can stimulate
UCP1 expression in fat tissue.
Phenotypic screens with adipocytes have proven to be a
powerful method to isolate small molecules that ameliorate the
symptoms of metabolic syndrome through novel mechanismshors
of action (Waki et al., 2007; Dominguez et al., 2014). To facilitate
the identification of pharmacologic agents to modulate UCP1
expression in adipocytes, we have generated a transgenic re-
porter mouse, ThermoMouse, in which luciferase activity reca-
pitulates the pattern of expression of UCP1 in vivo and allows
real-time visualization and quantification of UCP1 expression
in live animals. A chemical screen using brown adipocytes
derived from this model yielded a compound that can induce
UCP1 expression in cells and enhance UCP1 expression in vivo.
In response to adrenergic stimulation, mice treated with this
compound show increased energy expenditure. These results
demonstrate the utility of these models to identify pharmacolog-
ical modulators of UCP1 levels. Discovery of compounds with
this ability is an important stride toward the goal of enhancing
BAT function in obese individuals with drug-like molecules.
RESULTS
Development of a Transgenic Model to Image UCP1
Expression In Vivo
To develop an in vivo reporter system to monitor endogenous
UCP1 expression in a noninvasive manner, we generated trans-
genic mice that express luciferase2 under the control of the
Ucp1 genetic locus. A luciferase2-T2A-tdTomato cassette was
inserted at the initiation codon of theUcp1 gene in a 98.6 kb bac-
terial artificial chromosome (BAC) containing the entire Ucp1
gene locus (Figure S1A) and proper targeting confirmed (Fig-
ure S1B). Next, we used the IVIS Spectrum Imaging System to
monitor luciferase activity in transgenic mice generated using
this BAC construct. 3D imaging detected robust luciferase
signals in interscapular BAT, perirenal BAT, and inguinal WAT
(Figure 1A). No signals were detected in adipose depots of wild-
type mice (Figure S1C). To assess if luciferase activity recapitu-
lated endogenous UCP1 protein levels, we measured luciferase
activity and UCP1 protein in BAT, WAT, liver, and muscle. A tight
correlation was found between luciferase activity and endoge-
nous UCP1 protein expression (Figures 1B and 1C), indicating
that the reporter model mirrors the tissue distribution of UCP1.
To examine whether reporter mice responded to physiologic
stimuli known to induce UCP1 expression and BAT activity, we
monitored changes in luciferase activity during cold adaptation
(Figure 1D). Luciferase signal in interscapular BAT was low in
mice maintained at 28C (Figure S1D) but increased robustly in
mice kept at 9C for 24 hr (Figures 1D and 1E). Luciferase induc-
tion correlated with increases in UCP1 mRNA (Figure 1F) and
protein levels (Figure 1G). Similarly, subchronic (4 days) or acute
(1 day) treatment of reporter mice kept at 28C with a specific b3
adrenergic receptor agonist (CL-316,243; 1 mg/kg) dramatically
enhanced the luciferase signal and endogenous UCP1 protein
levels in BAT (Figures 1H and 1I). To evaluate the response of
beige cells in inguinal WAT, imaging was performed from a
side angle. Strong luciferase activity was detected in inguinal
WAT in response to chronic CL-316,243 treatment (Figure 1J).
The increase in signal was paralleled by robust induction of
UCP1 protein in this depot (Figure 1K). These results show that
our Ucp1 luciferase reporter accurately indicates changes in
UCP1 elicited by physiological responses and is a useful tool
to quantify changes in UCP1 expression in vivo.Cell ReA Cell-Based Screening Platform to Monitor UCP1
Protein Expression
Next, to establish a cell-based system for quantifying UCP1
expression in fat cells suited for screening of small-molecule
or genomic libraries, we generated immortalized preadipocyte
lines from Ucp1 luciferase transgenics. From six cell lines
derived from interscapular BAT, we selected one that showed
high adipogenic capacity and significant levels of UCP1 and
luciferase expression. Because PPARg ligands can stimulate
UCP1 expression (Sears et al., 1996), we tested the response
of this line to rosiglitazone. Luciferase activity was induced in a
dose-dependent manner and correlated tightly with endoge-
nous UCP1 protein levels (Figures 2A and 2B). Treatment
with the cAMP-signaling activator forskolin also increased
luciferase activity and UCP1 protein expression (Figures 2C
and 2D).
To confirm that theUcp1 luciferase reporter cell line preserved
the response to BAT activators, and that it could report sequen-
tial changes in UCP1 expression, nudemice were implanted with
Ucp1 luciferase preadipocytes subcutaneously and treated
6 days posttransplantation with saline or rosiglitazone (10 mg/
kg per day) for 7 days. Luciferase activity in transplants of rosigli-
tazone-treated mice was increased significantly at 4 days of
treatment and thereafter (Figures 2E and 2F). Transplanted pre-
adipocytes in mice treated with rosiglitazone formed discrete
adipose tissue containing multilocular adipocytes (Figure 2G,
upper left). These adipocytes were positive for UCP1 protein
(Figure 2G, upper right) and GFP (i.e., tdTomato; Figure 2G,
lower left), indicating that transplanted cells retained brown adi-
pogenic capacity in vivo. These observations indicate that this
cell-based system is a robust surrogate to assess endogenous
UCP1 expression.
A Small-Molecule Screen Identifies a Regulator of UCP1
Expression
To test the ability of our monitoring systems to identify regulators
of UCP1 expression, we performed a phenotypic screen using a
modestly sized library of small molecules, primarily carbamates
and triazole ureas (Adibekian et al., 2011; Bachovchin et al.,
2010). Ucp1 luciferase brown preadipocytes were seeded and
differentiated in 96-well plates. Mature adipocytes (day 8) were
incubated with compounds and luciferase activity quantified
16 hr later (Figure 3A). To evaluate the power of the assay to iden-
tify compounds that modulate UCP1 levels in either direction,
four hits with differing properties (activators and inhibitors)
were selected for study (Figure 3B). As it is often the case with
reporter-based screens, two hits could not be validated and
may represent, for example, nonspecific stabilizers of luciferase
signal. Of those that confirmed, compound 4 robustly increased
luciferase activity (Figure 3C). In contrast, compound 3 signifi-
cantly reduced luciferase signal. Importantly, compound 4
increased endogenous UCP1 protein expression to a similar
level to that induced by rosiglitazone (Figure 3D). None of the
compounds had any effect on brown preadipocytes (Figure S2).
Compound 4 (WWL113 in original nomenclature) was also a hit
in a different, image-based screen we recently described, in
which white preadipocytes were treated chronically (8 days)
during differentiation (Dominguez et al., 2014). WWL113 inhibitsports 9, 1584–1593, December 11, 2014 ª2014 The Authors 1585
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two serine hydrolases expressed in adipocytes, carboxylester-
ase 3 (Ces3 or Ces1d) and Ces1f (CesML1). However, the ability
of WWL113 to induce UCP1 expression in brown adipocytes
does not appear to be mediated by Ces3/1f inhibition, for a
structurally distinct Ces3 inhibitor (WWL229) failed to have the
same effect on UCP1 expression, whereas the urea version of
WWL113 (WWL113U), which does not inhibit Ces3, retained
the ability to induce UCP1 (Figure S3A). Nonetheless, we
concluded that WWL113 could be a valuable chemical probe
to further validate our reporter systems.
Induction of UCP1 Expression by WWL113 Relies on
PPARa Signaling
To characterize the effect of WWL113 on endogenous UCP1
expression, we treated cultured brown adipocytes with several
doses of WWL113. At a dose of 1 mM and higher, WWL113 sig-
nificantly increased UCP1 protein expression (Figure 4A). The
effect of WWL113 on UCP1 protein levels was largely due to
activation of Ucp1 transcription, because WWL113 powerfully
increased expression ofUcp1mRNA (Figure 4B).WWL113 treat-
ment also stimulated expression of mRNAs for other thermo-
genic genes, such as Cidea, Pgc1a, and Cox7a1 (Figure 4B).
WWL113 treatment had no effect on expression of the adipo-
genic marker Adiponectin. WWL113 treatment for 24 hr was suf-
ficient to activate endogenous Ucp1 mRNA expression without
affecting expression of multiple adipogenic markers (Figures
4C and S3B), indicating that WWL113 enhanced the BAT-selec-
tive thermogenic gene program in a cell-autonomous manner
without affecting adipogenesis per se. To test the functional con-
sequences of WWL113 treatment, we examined the extent to
whichWWL113 could sensitize brown adipocytes to physiologic
activators of BAT such as norepinephrine. WWL113 pretreat-
ment enhanced the increase inUcp1mRNA expression normally
induced by norepinephrine (Figure 4D). More importantly,
WWL113-treated cells showed greater total and uncoupled
respiration in response to norepinephrine and greater uncoupled
basal respiration (Figures 4E and S3C).
Next, we explored the mechanism by which WWL113
increased Ucp1 transcription. Because PPARa is a critical regu-
lator of thermogenic gene expression in BAT (Barbera et al.,
2001), we hypothesized that the action of WWL113 in BAT
could bemediated via PPARa. To test this notion, primary brown
adipocytes were treated with a selective PPARa antagonist
(GW6471) and/or a PPARg antagonist (GW9662) in the presence
or absence of WWL113. The capacity of WWL113 to increase
Ucp1 mRNA expression was largely blunted by treatment withFigure 1. Luciferase Imaging of UCP1 Expression In Vivo
(A) 3D reconstruction of luciferase signals in Ucp1 luciferase reporter mice. Adip
(B) Quantification of luciferase in adipose depots, skeletal muscle, and liver of m
(C) UCP1 protein expression in tissue lysates from the mouse in (B).
(D) Luciferase activity in Ucp1 luciferase reporter mice kept at 28C and subseq
(E) Quantification of luciferase signal in interscapular BAT of Ucp1 luciferase repo
(F)Ucp1mRNA expression in interscapular BAT ofUcp1 luciferase reporter mice k
(G) UCP1 protein expression in interscapular BAT of transgenic mice analyzed in
(H) Representative image of luciferase signal in Ucp1 luciferase reporter mice tre
(I) UCP1 protein expression in BAT of transgenic mice analyzed in (H).
(J) Representative images of luciferase signal in inguinal WAT depots of Ucp1 lu
(K) UCP1 protein expression in inguinal WAT depots of Ucp1 luciferase mice tre
Cell ReGW6471, but not with GW9662 (Figure 4F). The inhibitory effect
of GW6471 on WWL113-induced Ucp1 mRNA expression was
not altered when cells were cotreated with GW9662. These
results indicate that the ability of WWL113 to enhance Ucp1
expression is principally dependent on PPARa, but not PPARg,
activity. Because WWL113 is not a direct PPARa activator
(Dominguez et al., 2014), we tested the extent to which cotreat-
ment of differentiated brown adipocytes with WWL113 and a
PPARa agonist (GW9578) would further boost Ucp1 mRNA
levels. Cotreatment with WWL113 and GW9578 modestly but
significantly increased expression of Ucp1 relative to treatment
with either compound alone (Figure 4G), suggesting that
WWL113 cooperates with the PPARa pathway to enhance
UCP1 expression.
WWL113 Increases UCP1 Expression and the
Thermogenic Response In Vivo
We next tested if WWL113 could enhance UCP1 expression
in vivo. Ucp1 luciferase mice were treated with vehicle or
WWL113 (50 mg/kg once daily) for 5 days. This dose has been
shown to be effective in mice (Dominguez et al., 2014). A robust
and significant increase (5-fold) in Ucp1-driven luciferase
expression was detected in the interscapular BAT depots of
transgenic mice treated with WWL113 (Figures 5A and 5B).
To confirm these findings, we examined the ability of WWL113
to enhance thermogenic gene expression in C57BL/6J mice
treated with the compound for 5 days. WWL113 treatment
induced significant increases in mRNA expression of Ucp1 and
thermogenic genes, such as Pgc1a and Dio2, in the BAT of
wild-type mice (Figure 5C). No change in the general marker
Pparg was seen. Importantly, UCP1 protein expression was
highly induced in vivo byWWL113 (Figure 5D). In contrast, no dif-
ference in mRNA expression of Ucp1, Pgc1a, Dio2, and Pparg
was observed in inguinal WAT of WWL113-treated mice (Fig-
ure S5A), indicating that the effects of WWL113 on the thermo-
genic gene program may be specific to brown fat.
Finally, we examined the effects of WWL113 on whole-body
energy expenditure. Mice treated with WWL113 for 7 days
showed no differences in basal energy expenditure, but upon
adrenergic stimulation (CL-316,243 injection), they responded
with a more robust increase in energy expenditure than controls
(Figure 5E).WWL113 did not affect locomotor activity (Figure 5F),
food intake (Figure 5G), or heart rate (Figure 5H). These data indi-
cate thatWWL113 increased UCP1 levels in vivo to a functionally
meaningful degree, increasing the adaptive thermogenic capac-
ity of treated mice.ose depots with specific luciferase signal are indicated.
ice kept at room temperature. Values normalized to protein content.
uently kept at 9C for 24 hr. Representative mice are shown.
rter mice shown in (D) (n = 9). ***p < 0.001. Data are expressed as mean ± SEM.
ept at 28C and 9C for 24 hr. ***p < 0.001. Data are expressed asmean ±SEM.
(F).
ated with saline or CL-316,243 for 1 day (acute) or 4 days (subchronic; n = 3).
ciferase reporter mice treated with saline or CL-316,243 for 4 days.
ated with saline or CL-316,243 for 1 day or 4 days.
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Figure 3. Small-Molecule Screen to Identify
Regulators of UCP1 Expression
(A) Screen scheme. Ucp1 luciferase brown pre-
adipocytes were differentiated in 96-well plates
and treated at day 8 with compounds for 16 hr
(n = 3).
(B) Screen performance. Mean luciferase activity
of compounds (blue circles) plotted relative to the
value of DMSO-treated Ucp1 luciferase adipo-
cytes (100%; green circles). Rosiglitazone served
as positive control (red circles). Ucp1 luciferase
preadipocytes (purple circles) were used to
determine background and induction of signal
upon differentiation. Hits selected for evaluation
(blue circles, red outline) are numbered according
to the scheme used in validation experiments.
(C) Luciferase activity in differentiated Ucp1 lucif-
erase brown adipocytes treated with compounds
for 5 days. Rosiglitazone (0.5 mM) and CL-316,243
(10 nM) served as positive controls (n = 3). *p <
0.05; **p < 0.01; ***p < 0.001 versus control. Data
are expressed as mean + SD.
(D) UCP1 protein expression in cells from (C).DISCUSSION
We have developed an in vivo monitoring system that allows to
quantitatively track sequential changes in UCP1 expression
within the same individual. Because UCP1 expression shows a
high level of interindividual variation (Boeuf et al., 2002) and
changes dynamically during circadian oscillation (Gerhart-Hines
et al., 2013), seasonal changes (Au-Yong et al., 2009), and
aging (Rogers et al., 2012), this model may prove of wide utility.
18fluoro-labeled 2-deoxy-glucose positron emission tomogra-
phy (18FDG-PET) scanning has been applied to assess BAT ac-
tivity in rodents and humans (Cypess et al., 2009; Saito et al.,
2009; van Marken Lichtenbelt et al., 2009; Virtanen et al.,
2009), but detection of 18FDG-PET signals in BAT depends
entirely on glucose uptake. In contrast, the level of UCP1 expres-
sion in BAT is a more-direct measure of the thermogenic capac-
ity of this tissue (Nedergaard and Cannon, 2010). Hence, the
transgenic UCP1 reporter we describe provides an opportunity
to identify signaling pathways and transcriptional events that
control thermogenic capacity in brown adipocytes in vivo. Unlike
prior UCP1 models (Cassard-Doulcier et al., 1993), it also en-Figure 2. Cell-Based System to Monitor UCP1 Expression
(A) Luciferase activity in immortalized Ucp1 luciferase brown adipocytes. Differen
(n = 3).
(B) UCP1 protein expression in cells analyzed in (A).
(C) Luciferase activity in differentiated Ucp1 luciferase brown adipocytes treated
(D) UCP1 protein expression in cells analyzed in (C).
(E) Luciferase activity monitored at days 0, 1, 4, and 7 after the start of rosiglitazone
Saline (n = 4) or rosiglitazone (n = 6; 10 mg/kg) treatment started 6 days postimp
(F) Sequential changes in luciferase activity measured in fat transplants from mic
(G) Hematoxylin and eosin and immunofluorescent stains for UCP1 or GFP (i.e., td
GFP image counterstained with DAPI. The scale bar represents 50 mm. H&E, hem
*p < 0.05; **p < 0.01; ***p < 0.001. Data are expressed as mean ± SEM.
Cell Reables characterization of modulators of BAT function in real
time in live animals.
Ucp1 luciferase brown adipocyte lines derived from this trans-
genic retain the characteristics of bona fide brown fat cells.
A phenotypic screen using these cells identified a compound,
WWL113, that can increase UCP1 expression in vitro and in vivo.
It is important tonote thatUCP1’suncouplingactivity isdependent
on sympathetic nerve activation and increased intracellular cAMP
levels. As BAT activity is stimulated by cold exposure, long-chain
free fatty acids supplied from cAMP-induced lipolysis and from
the circulation directly bind UCP1 and serve as a substrate
to transport protons into the mitochondrial matrix (Fedorenko
et al., 2012). Thus, small molecules that solely stimulate UCP1
expression are unlikely to induce substantial thermogenesis. In
agreement with this notion, we found that the effect of WWL113
treatment oncellular respirationwasgreaterwhencellswere stim-
ulated with norepinephrine. In that setting, this chemical probe
significantly increased total and uncoupled cellular respiration.
More importantly, mice treated with WWL113 showed consider-
ably enhanced energy expenditure, but this increase required
adrenergic stimulation. WWL113-treated mice showed notiated adipocytes were treated with DMSO (control) or rosiglitazone for 5 days
with DMSO (control), forskolin, or rosiglitazone (0.5 mM) for 5 days (n = 3).
treatment inmice implanted withUcp1 luciferase immortalized preadipocytes.
lantation. Representative mice are shown.
e in (E).
Tomato) in transplants frommice treated with rosiglitazone. Merged UCP1 and
atoxylin and eosin staining.
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Figure 4. Effect of WWL113 on UCP1
Expression and Cellular Respiration
(A) UCP1 protein expression in differentiatedUcp1
luciferase brown adipocytes treated with WWL113
for 5 days. Rosiglitazone (0.5 mM) served as posi-
tive control.
(B) Expression of thermogenic genes in differenti-
ated Ucp1 luciferase brown adipocytes treated
with WWL113 (10 mM) for 5 days. Rosiglitazone
(0.5 mM) served as positive control (n = 3). *p <
0.05; ***p < 0.001 versus control.
(C) Ucp1 mRNA expression in primary differenti-
ated brown adipocytes treated with WWL113
(10 mM) or rosiglitazone (5 mM) for 24 or 48 hr (n =
3). ***p < 0.001 versus control.
(D) Ucp1 mRNA expression in primary differenti-
ated brown adipocytes treated with WWL113
(10 mM) or rosiglitazone (5 mM) for 48 hr. Norepi-
nephrine (0.1 mM) was added 8 hr prior to harvest
(n = 3). **p < 0.01; ***p < 0.001 versus control.
(E) Total and uncoupled (oligomycin-insensitive)
respiration of differentiated brown adipocytes (53
105 cells/sample) treated with WWL113 (10 mM) in
the presence or absence of norepinephrine
(0.1 mM; n = 3 to 4). *p < 0.05 versus control.
(F) Ucp1mRNA expression in differentiated brown
adipocytes treated with vehicle or WWL113
(10 mM) for 24 hr with or without 30 min pre-
treatment with a PPARa-selective antagonist
(GW6471; 3 mM) and/or a PPARg-selective
antagonist (GW9662; 10 mM; n = 3). ***p < 0.001
versus control. ###p < 0.001 versus WWL113-
treated cells.
(G)Ucp1mRNA expression in differentiated brown
adipocytes treated with vehicle, WWL113 (10 mM),
a PPARa-selective agonist (GW9578), or the
combination for 24 hr (n = 4). *p < 0.05; ***p <
0.001.
Data are expressed as mean + SD.differences in locomotor activity, food intake, or heartbeat, indi-
cating that the compound does not enhance basal sympathetic
drive. Together with the finding that WWL113 increases UCP1
expression in brown fat cells in a cell-autonomous manner, these
results suggest thatWWL113boosts energyexpenditureprimarily
by increasing the content of UCP1 in BAT that can be activated by
physiologic stimuli such as cold.
We previously reported that chronic administration (2 months)
of WWL113 to obese-diabetic mice reduced body weight gain,
improved systemic glucose and lipid homeostasis, and cleared
hepatic steatosis (Dominguez et al., 2014). We ascribed the
effects of WWL113 to inhibition of Ces3 in WAT and liver. Using
a distinct phenotypic screen as a starting point, in this study, we
have found that WWL113 can have Ces3-independent effects in1590 Cell Reports 9, 1584–1593, December 11, 2014 ª2014 The AuthorsBAT. WWL113 is not a direct activator of
PPARa (Dominguez et al., 2014), but its
effects on UCP1 expression in brown fat
cells depend to a large extent, though
not completely, on PPARa signaling.
Although the molecular target(s) for
WWL113’s action in BAT remains to beclarified, this tool compound has nonetheless demonstrated
the utility of our UCP1-monitoring systems to identify pharmaco-
logic activators of UCP1 expression.
BAT is the major adipose depot that contains UCP1-positive
adipocytes (classical brown adipocytes), but rodents and hu-
mans also possess an inducible type of thermogenic fat cells,
termed beige or brite adipocytes (Sharp et al., 2012; Wu et al.,
2012; Cypess et al., 2013; Lidell et al., 2013). UCP1-positive
beige adipocytes emerge within WAT in response to external
cues, such as sustained cold exposure or exercise. Beige adipo-
cytes are considered promising reservoirs for enhancing energy
expenditure, but current technologies (e.g., 18FDG-PET andMRI
scans) do not possess enough resolution to detect beige cells
in vivo. Our data indicate that our Ucp1 luciferase mouse may
Figure 5. WWL113 Increases UCP1 Expres-
sion in Mice
(A) Luciferase activity in Ucp1 luciferase reporter
mice treated daily with WWL113 (50 mg/kg) or
vehicle for 5 days (n = 5). Representative mice are
shown.
(B) Quantification of luciferase signal in inter-
scapular BAT of mice treated as in (A). Values
normalized to protein content and shown as fold
change relative to vehicle.
(C) Expression of thermogenic genes in inter-
scapular BAT of C57BL/6 mice treated daily with
WWL113 (50 mg/kg) or vehicle for 5 days (n = 5).
*p < 0.05; **p < 0.01
(D) UCP1 protein expression in interscapular BAT
of C57BL/6 mice analyzed in (C).
(E) VO2 of wild-type mice treated daily with
WWL113 (50 mg/kg) or vehicle for 7 days (n = 6).
CL-316,243 (1 mg/kg) was injected to examine the
response to adrenergic stimulation. **p < 0.01.
N.S., not significant.
(F) Locomotor activity of mice in (E).
(G) Food intake of mice in (E).
(H) Heart rate of mice in (E).
Data are expressed as means ± SEM.serve as a tool to monitor the effects of compounds and biolog-
ical factors on beige cells.
Although they share the thermogenic ability of brown adipo-
cytes, beige adipocytes have a distinct, heterogeneous develop-
mental origin that is not fully understood. Beige adipocytes in
multiple WAT depots can arise from Myf5-positive and negative
cells (Sanchez-Gurmaches and Guertin, 2014), and a subset of
inguinal beige adipocytes originates from a smooth-muscle
lineage (Long et al., 2014). Prior work has shown that regulation
of Ucp1 is distinct in the two types of thermogenic adipocytes
(Guerra et al., 1998; Koza et al., 2000; Xue et al., 2007). We found
that WWL113 could activate UCP1 expression in BAT, but
not in inguinal WAT, implying that WWL113-initiated signaling
events that regulate UCP1 expression may be unique to brown
adipocytes.
BAT and liver are the major organs responsible for triglyceride
uptake (Bartelt et al., 2011), and emerging evidence points to a
close connection between BAT activity, liver function, and sys-
temic lipid homeostasis. For example, defects in thermogenesis
caused by BAT-specific knockout of the enzyme euchromatic
histone-lysine N-methyltransferase 1 resulted in hepatic steato-
sis and insulin resistance, even when weight-matched miceCell Reports 9, 1584–1593, Dewere compared (Ohno et al., 2013).
Conversely, activation of BAT thermo-
genesis, for example by overexpression
of PTEN, reduced hepatic lipid accumula-
tion and enhanced systemic insulin sensi-
tivity (Ortega-Molina et al., 2012). Thus,
the therapeutic benefits of increased
BAT thermogenesis may not be limited
to effects on weight but could include
improvements in lipid homeostasis and
whole-body insulin sensitivity. The set oftools we have developed should aid the development of pharma-
cologically tractable approaches to activate BAT function as a
therapy against obesity and its complications.
EXPERIMENTAL PROCEDURES
Animals
Experiments were approved by the Institutional Animal Care and Use Commit-
tees of the University of California, San Francisco, and The Scripps Research
Institute. Unless stated, mice were kept at room temperature. WWL113 was
administered either intraperitoneally once daily (50mg/kg in a 4:1 PEG300:Tw-
een 80 vehicle solution) or orally (50 mg/kg in 0.5% hydroxypropylmethylcellu-
lose). At the conclusion of treatment, BAT, WAT, skeletal muscle, and liver
were snap frozen for luciferase assays and RNA and protein analysis. Energy
balance studies were performed over the course of 7 days using a Compre-
hensive Lab Animal Monitoring System (Columbus Instruments) as described
(Ohno et al., 2013). Data were normalized to body weight, as there were no dif-
ferences between groups. Heart rate in the conscious state was measured by
the indirect tail cuff method with a SC1000 MSP (Hatteras Instruments).
Generation of Ucp1 Luciferase Reporter Mice
A 98.6 kb BAC (bMQ353d13; Source BioScience) containing the entire Ucp1
gene locus was obtained and a luciferase2-T2A-tdTomato reporter cassette
(Addgene 32904) inserted at the initiation codon of theUcp1-coding sequence
located in exon 1 using BAC recombineering techniques (Warming et al.,cember 11, 2014 ª2014 The Authors 1591
2005). Ucp1 luciferase BAC DNA was microinjected into single-cell FVB
embryos and transgenic founders and their offspring identified by PCR
(primers provided in Table S1). Segregation patterns indicate that the trans-
gene inserted into the Y chromosome. Transgenics display no decrease in
fertility or any other abnormalities.
In Vivo Luciferase Imaging
Luciferase activity was monitored using an IVIS Spectrum Instrument (Caliper
Life Sciences). For 3D reconstruction, six images (exposure time: 180 s;
binning: L; F/Stop:1; emission filters: 560–660 nm; field of view: C) were
collected starting 8 min after injection of 150 mg/kg luciferin (Goldbio). In other
experiments, one image per scan (exposure time: 300 s; binning: M; F/Stop:1;
emission filters: open; field of view: D) was acquired 15min after luciferin injec-
tion. 3D reconstructions and luciferase activity were calculated using Living
Image Software (Caliper Life Sciences).
Immortalized Ucp1 Luciferase Adipocyte Lines
The stromal vascular fraction from interscapular BAT of 3-week-old male
UCP1 luciferase transgenic mice was isolated (Ohno et al., 2012) and cells
infected with a retrovirus expressing large T antigen (pBabe SV40 Large T an-
tigen; Addgene) and selected in puromycin (2 mg/ml). Immortalized preadipo-
cytes were cultured in Dulbecco’s modified Eagle’s medium (DMEM), 10%
fetal bovine serum (FBS), penicillin, and streptomycin. Upon 100% confluence
(day 0), differentiation was induced with medium containing 10% FBS, 5 mg/ml
insulin, 1 nM T3, 0.125 mM indomethacin, 2 mg/ml dexamethasone, and
0.125 mM 3-isobutyl-1-methylxanthine for 2 days. From day 2 on, cells were
cultured only in the presence of insulin and T3.
Phenotypic Screen
A library of approximately 300 compounds (Adibekian et al., 2011; Bachovchin
et al., 2010) was screened. ImmortalizedUcp1 luciferase brown preadipocytes
were seeded in 96-well plates and differentiated as described above. At day 8,
cells were exposed to compounds (5 mM for carbamates, 2.5 mM for triazole
ureas) in serum-free DMEM. Rosiglitazone (0.5 mM) served as positive control.
After 16 hr, media was replaced with Glo Lysis Buffer (Promega) and luciferase
activity quantified in a PHERAstar reader (BMG Labtech). Activity was normal-
ized relative to the signal in DMSO-treated cells in each plate. Assays were
performed in triplicate. Compounds inducing >50% increase or decrease in
luciferase activity were selected for follow-up.
Luciferase Assays
Cells or tissues were lysed in Cell Culture Lysis Reagent (Promega) and lucif-
erase activity quantified using the Luciferase Assay System (Promega). Activity
was measured in an Optocomp I reader (MGM Instruments) and normalized to
total protein content.
Gene Expression
Total RNA was isolated using RiboZol reagents (AMRESCO) and reversed
transcribed using an iScript cDNA synthesis kit (Bio-Rad) and quantitative
real-time PCR performed using SYBR green and an ABI ViiA7 machine. Rela-
tive mRNA expression was determined by the DD-Ct method with TATA-
binding protein as a normalization control. Primer sequences are provided in
Table S1.
Metabolic Studies
Whole-body energy expenditure was measured at ambient temperature using
a Comprehensive Lab Animal Monitoring System (Columbus Instruments) at
the University of California, San Francisco (UCSF) animal metabolic core facil-
ity. Wild-type mice were treated daily with WWL113 (50 mg/kg) or vehicle for
7 days (n = 6). The mice were injected intraperitoneally with a b3-adrenergic
receptor-specific agonist CL-316,243 at a dose of 1 mg/kg to examine the
response to adrenergic stimulation. VO2 was normalized by body weight.
Western Analysis
Proteomes were separated by SDS-PAGE. Antibodies used: UCP1 (Abcam;
ab10983); Akt (Cell Signaling Technology; 9272); a-tubulin (Sigma; T8203);
and b-actin (Sigma-Aldrich; AC-15).1592 Cell Reports 9, 1584–1593, December 11, 2014 ª2014 The AutCellular Respiration
Oxygen consumption rate was measured in a MT200A Cell Respirometer
(Strathkelvin), as previously described (Kajimura et al., 2009). Briefly, differen-
tiated brown adipocytes treated with DMSO orWWL113 (10 mM) for 48 hr were
trypsinized and incubated in serum-freemedium in the presence or absence of
norepinephrine. Uncoupled and nonmitochondrial cellular respiration were
measured using oligomycin (1 mM) and antimycin A (1 mM).
Fat Transplantation
Preadipocytes were implanted as described (Kajimura et al., 2009). Briefly,
cultured immortalized Ucp1 luciferase preadipocytes were trypsinized,
washed, and resuspended in PBS. Preadipocytes in a volume of 300 ml (4
3 107 cells) were injected subcutaneously into NCr nude mice (Taconic).
Six days after transplantation, mice were injected with either saline (n = 4) or
rosiglitazone (n = 6; 10 mg/kg) twice daily for 7 days. Luciferase activity was
monitored on days 0, 1, 4, and 7.
Histology
Tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sec-
tions (7 mm) were analyzed with hematoxylin and eosin staining and immuno-
fluorescence to detect UCP1 (ab10983 1:1,000 in 5% goat serum) or GFP
(GFP-1020 1:500 in 5% goat serum) as described (Sharp et al., 2012).
Statistics
Statistical significance was defined as p < 0.05 and determined by two-tailed
Student t tests, Wilcoxon, or ANOVA, with Dunne’s multiple comparison post
hoc analysis.
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